Rua Bioscience Ltd
NZX:RUA
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.023
0.059
|
| Price Target |
|
We'll email you a reminder when the closing price reaches NZD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| NZ |
|
Rua Bioscience Ltd
NZX:RUA
|
13m NZD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
530.8B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
278.2B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.8B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
222.3B CHF |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
267.6B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
147.1B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
97.2B EUR |
Loading...
|
Market Distribution
| Min | -1 380.2% |
| 30th Percentile | 2.6% |
| Median | 8.5% |
| 70th Percentile | 15.6% |
| Max | 98.6% |
Other Profitability Ratios
Rua Bioscience Ltd
Glance View
Rua Bioscience Ltd. operates as a pharmaceutical company that develops medical cannabis products. The company is headquartered in Gisborne, Gisborne. The company went IPO on 2020-10-22. The firm operate in the medicinal cannabis sector commercially and is focused on producing cannabinoid derived medicines. The firm is also focusing on cultivating and developing quality-assured medicinal cannabis as active pharmaceutical ingredients.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Rua Bioscience Ltd is -220.7%, which is above its 3-year median of -3 599.9%.
Over the last 3 years, Rua Bioscience Ltd’s Operating Margin has increased from -31 340.1% to -220.7%. During this period, it reached a low of -31 340.1% on May 30, 2022 and a high of -220.7% on Jul 30, 2025.